Unicycive Therapeutics, Inc. announced that it has entered into the securities purchase agreement that it will issue 50,000 shares of the Company?s Series B Convertible Preferred Stock at an issue price of $1,000 per share for the gross proceeds of $50,000,000 on March 14, 2024. All of the shares of Series B Convertible Preferred Stock, and the securities underlying such shares of Series B Convertible Preferred Stock, are being offered by company. The securities to be issued in connection with the private placement described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws.

Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.